REGULATORY

Nichi-Iko No. 1 in Terms of the Number of Generics Listed in June; Pfizer at 4th

June 22, 2012

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Nichi-Iko Pharmaceutical had the largest number of new products (including substitute products) added to the NHI price list in the June listing of generic drugs announced by the Ministry of Health, Labor and Welfare (MHLW) on June 22. Pfizer Japan,…

To read the full story

60% Rule Applied for 3 APIs in June’s Generic Listing
June 22, 2012

REGULATORY

Japan Mulls Target on “Social Security Burden Rate” after CEFP Call
May 25, 2026
Ishin Deepens Debate on Healthcare Macroeconomic Indexing
May 25, 2026
Update: Tavneos Slapped with Blue Letter Action in Japan over Liver Injury Risk
May 22, 2026
Blister Pack Supplies Seen Returning to Normal: Health Minister
May 22, 2026
LDP “Eto” Study Group Submits Honebuto Proposal to Health Minister
May 22, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises

By Hayate Horiguchi

Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…